MedTrace Logo

Dexmedetomidine in Erector Spinae Block in Postoperative Analgesia

NCT04920669 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2022-04-06

No results posted yet for this study

Summary

60 female patients scheduled for breast cancer surgeries, allocated in 3 groups for erector spinae block with bupivacaine and erector spinae block with dexmedetomidine added to bupivacaine and control group. During anesthesia: total intraoperative fentanyl required will be recorded. After surgery the first time of request for analgesic will be recorded. after request of analgesia all patients will be connected to PCA device containing morphine solution, the amount of morphine consumed during the first 24 hours will be recorded.

Conditions

  • Postoperative Pain

Interventions

PROCEDURE

erector spinae block with bupivacaine

Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%

PROCEDURE

erector spinae block with bupivacaine + dexmedetomidine

Patients will receive a sonar-guided erector spinae plane block with 19 ml of bupivacaine 0.5%+ 1 ml dexmedetomidine

Sponsors & Collaborators

  • Mohamed Elsayed Hassan

    lead OTHER

Principal Investigators

  • Mohamed E Hassan, MD · National Cancer Institute, Cairo University, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920669 on ClinicalTrials.gov